Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals Inc APLS
News
Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
Apellis Pharmaceuticals' stock slides 14% after company gets negative trend vote for eye treatment in Europe
Apellis Pharmaceuticals shares rally as competing eye treatment fails to impress analysts
United States